Biodesix, Inc. has announced that new research will be showcased at upcoming conferences, including the ISPOR 2025 Annual Meeting in Montreal and the ATS 2025 International Conference in San Francisco ...

(Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever conducted. This milestone strengthens the ...

CAMBRIDGE, England and MONTREAL, March 19, 2026 /PRNewswire/ -- CellCarta and Biofidelity today announce an expanded multi-year global strategic partnership, including exclusivity for Aspyre (R) Lung ...

LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (BDSX) (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society ...

CellCarta and Biofidelity today announce an expanded multi-year global strategic partnership, including exclusivity for Aspyre® Lung in clinical trial settings.

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, ...

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies’ (Nasdaq: BIAF; BIAFW) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the ...

Julie Harris had never been tested for lung cancer. A low-dose CT scan, the only recommended screening for adults at risk of developing lung cancer, was not something she’d ever found time to do. But ...

Biodesix (NASDAQ:BDSX) is focused on developing diagnostic tests intended to improve patient outcomes by answering specific clinical questions, Chief Financial Officer Robin Cowie said at a Barclays ...